New drug combo shows promise for rare breast cancer

NCT ID NCT03620643

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer that had lost a protein called E-cadherin. It also tested crizotinib alone in people with diffuse gastric cancer, triple-negative lobular breast cancer, or other tumors with a CDH1 gene mutation. The main goal was to see if the treatment could shrink tumors and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast lobular carcinoma Carcinoma, Lobular diffuse gastric cancer gastric cancer gastric neoplasm hormone receptor-positive breast cancer invasive lobular breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • Guys and St Thomas NHS Foundation Trust

    London, United Kingdom

  • Royal Marsden NHS Foundation Trust

    London, SW3 6JJ, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • University College London Hospital

    London, United Kingdom